Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

Inclusion Criteria:

• Current evidence of symptomatic GERD in accord with the Montreal definition.

• Patients must have had troublesome heartburn and/or regurgitation (with or withoutdyspepsia symptoms) of at least mild or moderate intensity on at least 5 days duringthe week before the start of screening.

Exclusion Criteria:

• Patients who have a history of drug, solvent or alcohol abuse.

• Patients who have suffered cardiac chest pain within the last year.

• Patients who have suffered a recent, significant unexplained weight loss of morethan 6 kg in the last 6 months.

• Female patients of childbearing potential who, for the duration of the study, areeither unwilling or unable to take adequate contraceptive precautions or areunwilling to be sexually abstinent.

• Pregnancy or lactating mother.

• Patients with a history and/or symptom profile suggestive of the following: anyother gastrointestinal (GI) disease, erosive GERD (Los Angeles classification gradesC-D), Barrett's oesophagus, acute peptic ulcer and/or ulcer complications,Zollinger-Ellison syndrome, gastric carcinoma, pyloric stenosis, oesophageal orgastric surgery, intestinal obstruction, current pernicious anaemia, indication forH. pylori eradication therapy, known gastrointestinal bleeding (hematochezia orhematemesis) within 3 months prior to the study, and severe diseases of other majorbody systems.

• Patients who were observed at screening to have a hiatus hernia with a diameterwhich exceeds 3 cm.

• Patients who have taken anti-cholinesterase drugs, traditional Chinese medicines fortreating gastrointestinal disease, ulcermin or misoprostol preparations within 7days prior to screening or throughout the study.

• Patients who have taken proton pump inhibitors (PPIs) during the 10 days prior toscreening, prokinetics or H2 antagonists during the 5 days prior to screening orsystemic glucocorticosteroids, non-steroidal anti-inflammatory drugs (except for lowdose aspirin which can be given for cardioprotection) on more than 3 consecutivedays or PPI-based triple or quadruple therapy for eradication of H-pylori during thelast 28 days.

• Patients taking or requiring to take macrolide antibiotics, such as erythromycin,azithromycin, from the day before screening.

• Patients with known hypophosphataemia, phenylketonuria or hypercalcaemia.

• Patients with severe constipation, or history of intestinal obstruction.

• In the opinion of the Investigator, patients with damaged heart or kidney functionand patients who require a low sodium diet.

• Any previous history of allergy or known intolerance to any of the investigationalmedicinal products.